Nonylphenol aggravates non-alcoholic fatty liver disease in high sucrose-high fat diet-treated rats

Jie Yu¹, Xuesong Yang², Xuefeng Yang³, Mengxue Yang⁴, Pan Wang⁵, Yu Yang¹, Jing Yang¹, Wenmei Li² & Jie Xu¹

Exposure to environmental endocrine disruptors (EEDs) contributes to the pathogenesis of many metabolic disorders. Here, we have analyzed the effect of the EED-nonylphenol (NP) on the promotion of non-alcoholic fatty liver disease (NAFLD) in rats fed high sucrose-high fat diet (HSHFD). Fifty Sprague-Dawley rats were divided into five groups: controls fed a normal diet (C-ND); HSHFD-fed controls (C-HSHFD); and rats fed a HSHFD combined with NP at doses of 0.02 μg/kg/day (NP-L-HSHFD), 0.2 μg/kg/day (NP-M-HSHFD), and 2 μg/kg/day (NP-H-HSHFD). Subchronic exposure to NP coupled with HSHFD increased daily water and food intake (p < 0.05), hepatic echogenicity and oblique liver diameter (p < 0.05), and plasma levels of alanine aminotransferase, aspartate aminotransferase, total cholesterol, triglycerides, and low density lipoprotein cholesterol (p < 0.05). Combined exposure to NP and HSHFD induced macrovesicular steatosis with dilation and congestion of the central vein, liver inflammatory cell infiltration, and expression of genes regulating lipid metabolism, SREBP-1C, FAS, and Ucp2. These results demonstrate that NP aggravates NAFLD in HSHFD-treated rats by up-regulating lipogenic genes, and that HSHFD increases the toxic effects of NP. Thus subchronic NP exposure may lead to NAFLD, especially when combined with a high-sucrose/high-fat diet.

Non-alcoholic fatty liver diseases (NAFLD) encompass a wide range of liver pathologies from simple steatosis to steatohepatitis and cirrhosis¹, which may result in hepatocellular carcinoma. NAFLD is frequently associated with insulin resistance, dyslipidemia, obesity, and the metabolic syndrome². Following the epidemics of obesity, NAFLD is emerging as an important public health issue in the world. The highest prevalence of NAFLD with figures ranging between 30 to 50% was reported in South American and Mexican populations³. In China, NAFLD is one of the leading etiologies of chronic liver diseases, with a prevalence ranging from 15.9%⁴ to 43.3%⁵ in the general population.

The pathogenesis of NAFLD is multifactorial with strong genetic and environmental contributions, such as unbalanced diets, over-nutrition, as well as sedentary lifestyles⁶. The potential effect of environmental endocrine disruptors (EEDs) on the increased incidence of NAFLD has raised a concern in recent years⁷. Nonylphenol (NP) is a well-known environmental endocrine disrupting chemical with weak estrogenic activity⁸, which is used in detergents, emulsifiers, and wetting agents in industry, but is also found in paints, pesticides, and household toiletries⁹. NP has been detected in human urine samples¹⁰ and adipose tissues¹¹. Studies have suggested that NP has deleterious effects on endocrine¹², reproductive¹³, immune¹⁴, and nervous¹⁵,¹⁶ systems in animals and humans.

Recent studies have indicated that exposure to EEDs is associated with an increased risk of metabolic disorders¹⁷,¹⁸, such as steatosis¹⁹, obesity²⁰,²¹, insulin resistance²², and type 2 diabetes²³. Wei et al. have demonstrated that bisphenol A exposure during the perinatal period exacerbated non-alcoholic steatohepatitis-like phenotype in high-fat diet (HFD)–treated male rat offspring²⁴. In another study, Boucher et al. have found that polychlorinated biphenyls (PCB) interfere with the normal functioning of vital metabolic pathways in the liver and are associated with the development of NAFLD²⁵. In addition, in our previous study, histopathological study in the liver revealed...
steatosis with hepatocellular ballooning degeneration in rats exposed to HSHFD plus NP26. Nonetheless, the effect of NP on the promotion of NAFLD development has not been demonstrated yet. Therefore, the present study was designed to test the hypothesis that subchronic NP exposure causes a predisposition to NAFLD. Specifically, we tested whether a combination of NP and high-sucrose/high-fat diet interacts in an additive or an antagonistic way.

Materials and Methods

Ethics Statement. Animal experimental procedures were approved by Zunyi Medical University Ethics Committee. All methods were performed in accordance with guidelines and regulations of the Zunyi Medical University.

Animals and experimental protocol. Fifty Sprague-Dawley (SD) rats were obtained from the Animal Center of the Third Military Medical University (Chongqing, China), and received chow diet for 4 weeks. The rats (half males and half females) were randomly divided into 5 groups, each group had 10 rats. The rats were treated for 90 days. The first group fed with a normal diet (SCXK 2012–0012) (C-ND). The rats gavaged with groundnut oil alone (2 ml/kg/day). The second group fed with a high-sucrose/high-fat diet (SCXK2012–0012) (C-HSHFD). The third, fourth, and fifth groups were fed high-sucrose/high-fat diets with increasing concentrations of NP (half males and half females) were randomly divided into 5 groups, each group had 10 rats. The rats were treated for 90 days. The first group fed with a normal diet (SCXK 2012–0012) (C-ND). The rats gavaged with groundnut oil alone (2 ml/kg/day). The second group fed with a high-sucrose/high-fat diet (SCXK2012–0012) (C-HSHFD). The third, fourth, and fifth groups were fed high-sucrose/high-fat diets with increasing concentrations of NP (half males and half females) were randomly divided into 5 groups, each group had 10 rats. The rats were treated for 90 days. The first group fed with a normal diet (SCXK 2012–0012) (C-ND). The rats gavaged with groundnut oil alone (2 ml/kg/day). The second group fed with a high-sucrose/high-fat diet (SCXK2012–0012) (C-HSHFD). The third, fourth, and fifth groups were fed high-sucrose/high-fat diets with increasing concentrations of NP (Tokyo Chemical Co., Ltd, Tokyo, Japan, purity > 99%), which was dissolved in groundnut oil at dose levels of 0.02 μg/kg/day (NP-L-HSHFD), 0.2 μg/kg/day (NP-M-HSHFD), or 2 μg/kg/day (NP-H-HSHFD). The ingredient of HSHFD was lard (15%), sugar (25%) and a normal diet (65%). The rats were raised under controlled temperature (20 ± 1 °C) and humidity (60 ± 5%), on a 12 – hr light (09:00–21:00 hr), 12 – hr dark (21:00–09:00 hr) cycle. Food and water were unlimitedly supplied to the animals.

Measurement of body weight and hepatosomatic index (HSI). The body weight of rats was measured on day 90. The HSI was calculated as the ratio of the liver weight to the total body weight (HSI = liver weight/total body weight × 100).

Detection of liver oblique diameter. On day 80, Doppler color ultrasound (Philips Ultrasound, CA, USA) was used to detect the liver oblique diameter of rat and identify the rats with fatty liver27.

Biochemical measurement. Pentobarbital sodium at a dose of 20 mg/kg was intraperitoneally injected to rats to induce anesthesia. Blood serum was gathered from the abdominal aorta for biochemical studies on day 90. Plasma alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol (TC), triglyceride (TG), and low density lipoprotein cholesterol (LDL-C) activities were measured using a biochemical kit with an automatic biochemical analyzer (Beckman Coulter, Villepinte, France).

Histopathology. The rats were euthanized by cardiac arrests, and liver tissues were gathered on day 90. Liver specimens were fixed in 10% formalin and stained with hematoxylin-eosin (HE) to detect hepatic steatosis and inflammation28.

Detection of fatty acid synthase (FAS), sterol regulatory element-binding protein 1 (SREBP1) and uncoupling protein 2 (UCP2) mRNA in liver tissue by RT-PCR. Total RNA of lung tissue was extracted using TRIzol (Invitrogen, Diego, CA, USA). Reverse transcriptase was from Invitrogen (Diego, CA, USA), thermal cycler was from Biometra (Goettingen, Germany, model: T1-Thermoblock), and electrophoresis apparatus and gel imager were from Bio-Rad (Hercules, CA, USA). The levels of FAS, SREBP1, and UCP2 were expressed relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH)29. The sequences of the primers used are listed in Table 1.

Table 1. The sequences of the primers.

| Gene name | Sequences | Gene ID |
|-----------|-----------|---------|
| FAS       | Forward: CTCCTGGAAAGTGCATGCTGTAAGA | 246097  |
|           | Reverse: GGTAGAATGCATTGGGAAAGGT   |         |
| SREBP1    | Forward: CATCGACTCATCCGGCTCTTCA   | 78968   |
|           | Reverse: GTCTTTACTGGATTTTGGTTGA   |         |
| UCP2      | Forward: TGTGTGAAAAGTCCCGCTTCC   | 54315   |
|           | Reverse: TTTCCGGCAACATGTTGGAG    |         |
| β-actin   | Forward: CAACGGCTCCGGCATGTGC     | 0311442 |
|           | Reverse: CTCTTGCTCTGGGCCCTCG     |         |

Detection of peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT/enhancer-binding protein α (C/EBPα) in liver tissue by western blotting. Western blotting was performed according to standard procedures. Briefly, cells were lysed in a lysis buffer containing 50 mM Tris-HCl (pH 8.0), 0.4% Nonidet P - 40, 120 mM NaCl, 1.5 mM MgCl2, 0.1% sodium dodecyl sulfate (SDS), 2 mM phenylmethylsulfonyl fluoride, 80 μg/mL leupeptin, 3 mM NaF and 1 mM dithiothreitol (DTT). Cell lysates (50 μg protein) were separated by 10% SDS-polyacrylamide gel electrophoresis, transferred onto a polyvinylidene fluoride membrane, blocked with 5% skim milk, and incubated with primary antibodies. PPARγ and C/EBPα antibodies were from Abcam (Cambridge, MA, USA) and the monoclonal β-actin antibody was from Chemicon.
Horseradish peroxidase (HRP)-labelled mouse anti-rabbit IgG was from Jackson ImmunoResearch (West Grove, PA, USA). After incubation with HRP-conjugated secondary antibody at room temperature, immunoreactive proteins were detected using a chemiluminescent ECL Assay Kit (Amersham Pharmacia, Little Chalfont, England, UK) according to the manufacturer's instructions.

### Statistical analysis.

SPSS18.0 packed programs for Windows (SPSS Inc., Chicago, IL, USA) was used to perform all calculations. Data are expressed as mean ± standard deviation. The One-way analysis of variance (ANOVA) test and Student–Newman–Keuls (SNK) test were used for the evaluation of differences among the treatment groups. A P-value < 0.05 among groups was considered as the level of statistical significance.

### Results

#### Body weight and HSI.

The rats treated with HSHFD (C-HSHFD, NP-L-HSHFD, NP-M-HSHFD and NP-H-HSHFD) for 90 days had significantly increased body weight in comparison with control C-ND group (F = 10.477, p = 4.39E-6). The weight gain in the NP-H-HSHFD group was higher than that in the C-HSHFD group (p = 0.009; Fig. 1).

There was no significant difference in the hepatosomatic index (HSI) between the individual groups (p > 0.05; Fig. 2).

#### Daily volume of water consumed.

Exposure to C-HSHFD, NP-L-HSHFD, NP-M-HSHFD and NP-H-HSHFD induced an increase in the daily volume of water consumed, as compared to the C-ND group (F = 80.61, p = 6.27E-20). Exposure to NP-L-HSHFD, NP-M-HSHFD and NP-H-HSHFD significantly increased the daily volume of water consumed in comparison with the C-HSHFD group (p < 0.05; Fig. 3).

#### Daily food intake.

Exposure to C-HSHFD and NP-L-HSHFD decreased the daily food intake in comparison with the C-ND group (p < 0.05). However, NP-M-HSHFD and NP-H-HSHFD exposure increased the daily food intake in comparison with the C-HSHFD group (p < 0.05, Fig. 4).

#### Ultrasound imaging.

No obvious abnormal alterations were observed in the liver tissue of C-ND group. Increased hepatic echogenicity was observed in the C-HSHFD, NP-L-HSHFD, NP-M-HSHFD, and NP-H-HSHFD groups (arrowheads), which identified the rats with fatty liver. There was increased hepatic echogenicity in the NP-M-HSHFD and NP-H-HSHFD groups in comparison with the C-HSHFD group, indicating that NP-M-HSHFD and NP-H-HSHFD exposure results in worse fatty liver (Fig. 5).
Liver oblique diameter in the NP-M-HSHFD (21.80 ± 1.47 mm) and NP-H-HSHFD (22.12 ± 2.13 mm) groups rather than NP-L-HSHFD (21.15 ± 1.69 mm) was significantly larger than that in the C-HSHFD (20.35 ± 0.47 mm) group (p < 0.05). Liver oblique diameter in the C-ND group (18.62 ± 0.45 mm) was smaller than that in the NP-L-HSHFD, NP-M-HSHFD and NP-H-HSHFD groups (p < 0.05; Fig. 6).

Plasma markers. Exposure to C-HSHFD, NP-L-HSHFD, NP-M-HSHFD and NP-H-HSHFD increased plasma ALT and AST levels in comparison with the C-ND group (p < 0.05). Exposure to NP-H-HSHFD increased plasma ALT and AST levels in comparison with the C-HSHFD group (p < 0.05; Fig. 7). Exposure to C-HSHFD, NP-L-HSHFD, NP-M-HSHFD, and NP-H-HSHFD increased plasma TC, TG, and LDL-C concentrations in comparison with the C-ND group. NP-H-HSHFD exposure increased plasma TC, TG and LDL-C levels in comparison with the C-HSHFD group (p < 0.05; Fig. 8).

Histopathological changes in liver tissue. The hepatic cells in the C-ND group had a normal morphology. The appearance of hepatocytes, central vein, and portal areas appeared normal. Further, there was no evidence of inflammatory cell infiltration.

Exposed to NP-H-HSHFD induced macro-vesicular steatosis (arrowheads). There were the accumulation of lipid droplets in the cytoplasm, dilation and congestion of central vein, and inflammatory cell infiltration in the NP-H-HSHFD group (Fig. 9).

Effect of NP and HSHFD on gene expression of SREBP1, FAS, and UCP2 in liver. Compared to the control C-ND and C-HSHFD groups, expression of liver SREBP1 mRNA was increased in the groups fed with NP, even though it reached statistical significance only in the NP-M-HSHFD group (Fig. 10). Expression of FAS mRNA in the groups fed with NP was increased compared to the C-HSHFD group (p < 0.05). Similarly, expression of UCP2 mRNA was increased in the groups fed with NP compared to the C-HSHFD group (p < 0.05).

Effect of NP and HSHFD on protein levels of C/EBPα and PPARγ in liver. The protein levels of C/EBPα were increased in the groups fed with NP in comparison with the C-HSHFD group (p < 0.05). PPARγ protein levels were increased only in the NP-M-HSHFD and NP-H-HSHFD groups compared to the C-HSHFD group (p < 0.05; Fig. 11).
Figure 5. Ultrasound imaging of Liver. (A) C-ND group; (B) C-HSHFD group; (C) NP-L-HSHFD group; (D) NP-M-HSHFD group; E: NP-H-HSHFD group.

Figure 6. Difference of liver oblique diameter among treatment groups (n = 10). *p < 0.05 vs C-ND; †p < 0.05 vs C-HSHFD.

Figure 7. Comparisons in ALT and AST among treatment groups (n = 10). *p < 0.05 vs C-ND; †p < 0.05 vs C-HSHFD.
In addition to genetic susceptibility, environmental factors, such as diet and lifestyle, play an important role in the pathogenesis of progressive NAFLD. Nonylphenol (NP) is a common environmental contaminant that is known to disrupt the endocrine system. NP can enter the body by ingestion or adsorption, and may mimic estrogenic activity.

**Figure 8.** Comparisons in TG, TC and LDL-C among treatment groups (n = 10). *p < 0.05 vs C-ND; *p < 0.05 vs C-HSHFD.

**Figure 9.** Histopathological results in the liver (200×). (A) C-ND group; (B) C-HSHFD group; (C) NP-L-HSHFD group; (D) NP-M-HSHFD group; (E) NP-H-HSHFD group.

**Figure 10.** Expressions of FAS, SREBP1 and UCP2 mRNA in liver (n = 10). *p < 0.05 vs C-ND; *p < 0.05 vs C-HSHFD.

**Discussion**
In addition to genetic susceptibility, environmental factors, such as diet and lifestyle, play an important role in the pathogenesis of progressive NAFLD. Nonylphenol (NP) is a common environmental contaminant that is known to disrupt the endocrine system. NP can enter the body by ingestion or adsorption, and may mimic estrogenic activity.
action. Consequently, estrogen-like actions of NP have accounted for its adverse effects, such as reproductive malformations, incapacity of offspring to react to certain behavioral stimuli, and metabolic dysregulation. However, until recently, little information on the metabolic effects of subchronic NP exposure was available. Therefore, in this study, we have investigated the effect of environmentally used concentrations of NP, together with HSHFD, on the pathogenesis of NAFLD.

Our results show that the combined exposure to NP and high sucrose-high fat diet results in metabolic disorders, including increased body weight, daily food intake and volume of water consumed, and hepatic echogenicity and liver oblique diameter, demonstrating that NP induces NAFLD in rats. In addition, our data demonstrate that HSHFD promoted the adverse effects of NP. Our data show hepatic steatosis with inflammatory cell infiltration in the NP-H-HSHFD group, indicating that a high-sucrose/high-fat diet combined with NP exposure could cause non-alcoholic steatohepatitis (NASH). Additionally, since the percentage of steatosis increased with the NP concentrations, these data indicate that the degree of NP exposure correlates with the degree of NAFLD steatosis in rats fed with HSHFD.

Increased serum ALT and AST levels serve as markers of the liver damage caused by EEDs. The LDL is the major transport vehicle for TG in the blood. Our results showed that the administration of NP coupled with HSHFD increased the plasma levels of ALT, AST, TG, TC, and LDL-C, indicating that the exposure to NP causes a severe disturbance of lipid and protein metabolism. Our observations are in line with previous studies demonstrating the enhanced effect of other EEDs on lipid metabolism disorder in liver tissue. Our study indicates that NP might regulate the lipid metabolism in adipocytes.

Our results also showed that exposure to NP increased expression of SREBP1, FAS, and UCP2 mRNA. SREBP1 is an important liver transcription factor that regulates lipid synthesis and enzymes (e.g., fatty acid synthase) catalyzing various steps in the FA and TG synthesis pathways. SREBP-1c-activated lipogenesis has been suggested to contribute to NAFLD. FAS catalyzes lipid synthesis in the cytosol, while UCP2, an anion carrier, inhibits mitochondrial membrane potential and ATP synthesis. Our results demonstrate that NP exposure increases expression of fat synthesis-related genes, suggesting that NP may increase the lipid levels via the upregulation of SREBP1, FAS and UCP2 gene expression in the liver. These data are consistent with a previous study, which demonstrated that gene expression of SREBP-1C and FAS was increased in liver of EEDs-exposed rats.

PPARγ is predominantly expressed in adipose tissues, and is considered as the key regulator of adipocyte differentiation and adipogenesis. C/EBPα is a key transcriptional regulator that plays an important role during adipocyte differentiation and function. A recent study has demonstrated that in 3T3-L1 adipocytes differentiated in the presence of BPA, the expression of PPARγ and C/EBPα was increased. The current study found that NP-HSHFD combined exposure was associated with the increased expressions of PPARγ and C/EBPα, suggesting that NP induces pre-adipocyte differentiation through altering the expression of these transcription factors. These observations are in accordance with previous publications demonstrating increased expression of PPARγ proteins in the fat tissues of EEDs (i.e., tributyltin chloride (TBT))-treated rats. Importantly, our findings provide the first evidence of altered gene expression in the liver after combined exposure to NP and high sucrose-high fat diet.

The unit of NP exposure dose in prior studies was milligram (mg), which was far above actual environmental exposure level. For example, NP exposure doses changed from 50 mg/kg/day to 200 mg/kg/day in...
our toxicological studies. Specifically, our previous study shown that the concentration of NP measured in Xiangjiang River in Zunyi of China ranges from 0.174 to 3.411 μg/L. In light of the findings, the NP gavage doses of 0.02 μg/kg - 2 μg/kg in rats were designed in this study. In addition, exposure time for NP were short-term acute or subacute period in previous studies, which was far shorter than the actual exposure time. In order to make up the above shortcomings, the current study designed low environmental exposure concentration and subchronic exposure time, respectively.

The objective of our prior study was to explore quantitatively whether NP exposure might induce NAFLD, therefore, only single NP exposure dose (180 mg/kg/day) was designed, and the unit of NP exposure dose was milligram. The current study is the extension and expansion of the prior study, which has two main differences from the former one: 1. the design of exposure dose. In the current study, NP exposure dose was close to human exposure level, which is microgramme level, and three levels of NP treatment dose were designed to observe a dose-effect relationship. 2. The exploration of mechanism. The detection indicators of lipid metabolism-related genes and proteins in liver were added on the basis of the former study.

In conclusion, the present study demonstrates that prolonged exposure to low NP dose coupled with a HSHFD aggravates NAFLD in rats, as evidenced by increased body weight, increased daily volume of water consumed and daily food intake, increased hepatic echogenicity and oblique diameter of the liver, and increased plasma levels of ALT, AST, TC, TG and LDL-C. Moreover, exposure to NP induces inflammatory cell infiltration in the liver, and increases expression of SREBP1, FAS, and UCP2 in hepatocytes. Importantly, HSHFD promoted the adverse effects of NP. Together, our study indicates that subchronic NP exposure may lead to NAFLD, especially when combined with high-sucrose/high-fat diet.

References
1. Heidari, Z. & Gharebaghi, A. Prevalence of Non Alcoholic Fatty Liver Disease and its Association with Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus. J Clin Diagn Res. 11, OC04–OC07 (2017).
2. Byrne, C. D. & Targher, G. NAFLD: a multisystem disease. J Hepatol. 62, S47–S64 (2015).
3. Saab, S., Manne, V., Nieto, J., Schwimmer, J. B. & Chalasani, N. P. Nona-Alcoholic Fatty Liver Disease in Latinos. Clin Gastroenterol Hepatol. 14, 5–12 (2016).
4. He, S. et al. Risk factors for non-alcoholic fatty liver disease in a Chinese population. Acta Gastroenterol Belg. 74, 503–508 (2011).
5. Zhai, H. L. et al. Low vitamin D levels and non-alcoholic fatty liver disease, evidence for their independent association in men in East China: a cross-sectional study (Survey on Prevalence in East China for Metabolic Diseases and Risk Factors (SPECT-China)). Br J Nutr. 115, 1352–1359 (2016).
6. Mariana, V. M. & Helena, C. P. Non-alcoholic fatty liver disease: What the clinician needs to know. World J Gastroenterol. 20, 12956–12980 (2014).
7. Yan, H. M., Gao, X. & Liu, M. Study of the association between non-alcoholic fatty liver disease and metabolic syndrome. Chinese Journal of Diabetes. 14, 326–328 (2006).
8. Yu, J. et al. The effects of gestational and lactational exposure to Nonylphenol on c-jun, c-fos and learning and memory in hippocampus in male F1 rat. Iranian Journal of Basic Medical Sciences. 20, 386–391 (2017).
9. Yu, J. et al. Mechanism of nonylphenol-induced neurotoxicity in F1 rats during sexual maturity. Wien Klin Wochenschr. 128, 426–434 (2016).
10. Jing, X., Bing, S., Xiaoyan, W., Xiaojie, S. & Yongning, W. A study on bisphenol A, nonylphenol, and octylphenol in human urine samples detected by SPE/PLC–MS. Biomed. Environ. Sci. 24, 40–46 (2011).
11. Ferrara, F., Ademollo, N., Ottori, M. A., Silvestroni, L. & Funari, E. Alkylphenols in adipose tissues of Italian population. Chemosphere. 82, 1044–1049 (2011).
12. Verner, M. A., Magher, T. & Haddad, S. High concentrations of commonly used drugs can inhibit the in vitro glucuronidation of bisphenol A and nonylphenol in rats. Xenobiota. 40, 83–92 (2010).
13. Kazemi, S., Feizi, F., Aghapour, F., Joorsaraee, G. A. & Moghadamnia, A. A. Histopathology and Histomorphometric Investigation of Bisphenol A and Nonylphenol on the Male Rat Reproductive System. J Am Med Sci. 8, 215–221 (2016).
14. Xu, J. et al. Immune effects of nonylphenol on offspring of rats exposed during pregnancy. Hum. Ecol. Risk Assess. 16, 444–452 (2010).
15. Coudere, M. et al. Neurodevelopmental and behavioral effects of nonylphenol exposure during gestational and breastfeeding period on F1 rats. Neurotoxicology. 44, 237–249 (2014).
16. Yu, J. et al. Joint neurodevelopmental and behavioral effects of nonylphenol and estradiol on F(1) male rats. Int J Environ Heal Res. 23, 321–330 (2013).
17. Lee, H. A., Park, S. H., Hong, Y. S., Ha, E. H. & Park, H. The Effect of Exposure to Persistent Organic Pollutants on Metabolic Health among KOREAN Children during a 1-Year Follow-Up. Int J Environ Res Public Health. 13, E270 (2016).
18. Zhang, H. Y. et al. Perinatal exposure to 4-nonylphenol affects adipogenesis in first and second generation rats offspring. Toxicol Lett. 225, 325–332 (2014).
19. Anoumame, K. et al. Effects of 4-nonylphenol on oxidant/antioxidant balance system inducing hepatic steatosis in male rat. Toxicol Rep. 2, 1432–1433 (2015).
20. Hao, C. J., Cheng, X. J., Xia, H. F. & Ma, X. The endocrine disruptor 4-nonylphenol promotes adipocyte differentiation and induces obesity in mice. Cell Physiol Biochem. 30, 382–394 (2012).
21. Tran, V. et al. Prenatal phthalate exposure and 8-isoprostane among Mexican-American children with high prevalence of obesity. J Dev Orig Health Dis. 8, 196–205 (2017).
22. Ceng, S. et al. Curcumin attenuates BPA-induced insulin resistance in HepG2 cells through suppression of JNK/p38 pathways. Toxicol Lett. 272, 75–83 (2017).
23. Saponaro, C., Gaggini, M. & Gastaldelli, A. Nona-Alcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms. Curr Diab Rep. 15, 607 (2015).
24. Wei, J. et al. Perinatal exposure to bisphenol A accelerates non-alcoholic steatohepatitis-like phenotype in male rat offspring fed on a high-fat diet. J Endocrinol. 222, 313–325 (2014).
25. Boucher, M. P., Lefebvre, C. & Chapados, N. A. The effects of PCB126 on intra-hepatic mechanisms associated with non alcoholic fatty liver disease. J Diabetes Metab Disord. 14, 88 (2015).
26. He, J. et al. Ascent of chronic exposure to nonylphenol on non-alcoholic fatty liver disease in male rats. PLoS One. 12, e0180218 (2017).
27. Zhou, Y. C. & Ge, W. X. UltrasoundMedicine, 4th edition. Beijing Science and Technology Literature Press. (2007).
28. Acedo, S. C. et al. Role of pentoxifylline in non-alcoholic fatty liver disease in high-fat diet-induced obesity in mice. World J Hepatol. 7, 2551–2558 (2015).

NAFLD: non-alcoholic fatty liver disease; HSHFD: high-sucrose/high-fat diet; NAFLD: non-alcoholic fatty liver disease; NP: Nonylphenol; T1: first generation offspring.
34. Avci, B., Bahadir, A., Tuncel, O. K. & Bilgici, B. Influence of α-tocopherol and α-lipoic acid on bisphenol-A induced oxidative damage in liver and ovarian tissue of rats. *Toxicol Ind Health*. **32**, 1381–1390 (2016).

35. Jin, Y., Zeng, Z., Wu, Y., Zhang, S. & Fu, Z. Oral Exposure of Mice to Carbendazim Induces Hepatic Lipid Metabolism Disorder and Gut Microbiota Dysbiosis. *Toxicol Sci*. **147**, 116–126 (2015).

36. Guzger, K. J. et al. Mice deficient in Sfrp1 exhibit increased adiposity, dysregulated glucose metabolism, and enhanced macrophage infiltration. *PLoS One*. **8**, e78520 (2013).

37. Awazawa, M. et al. Adiponectin suppresses hepatic SREBP1c expression in an AdipoR1/LKB1/AMPK dependent pathway. *Biochem Biophys Res Commun*. **382**, 51–56 (2009).

38. Zou, X. et al. Mitochondrial dysfunction in obesity-associated nonalcoholic fatty liver disease: the protective effects of pomegranate with its active component punicalagin. *Antioxid Redox Signal*. **21**, 1557–1570 (2014).

39. Puig, T. et al. Fatty acid metabolism in cancer cells: Differential inhibitory effects of epigallocatechin and C75. *Breast Cancer Res Treat*. **109**, 471–479 (2008).

40. Mitchell, A. et al. Uncoupling protein 2 polymorphisms as risk factors for NTDs. *Birth Defects Res A Clin Mol Teratol*. **85**, 156–160 (2009).

41. Somm, E. et al. Perinatal exposure to bisphenol a alters early adipogenesis in the rat. *Environ Health Perspect*. **117**, 1549–1555 (2009).

42. Stechschulte, L. A. et al. FKBPs1 Null Mice Are Resistant to Diet-Induced Obesity and the PPARY, Agonist Rosiglitazone. *Endocrinology*. **157**, 3888–3900 (2016).

43. Ariemma, F. et al. Low-Dose Bisphenol-A Impairs Adipogenesis and Generates Dysfunctional 3T3-L1 Adipocytes. *PLoS One*. **11**, e0130762 (2016).

44. Bertoloso, R. D. et al. Tributyltin chloride leads to adiposity and impairs metabolic functions in the rat liver and pancreas. *Toxicol Lett*. **235**, 45–59 (2015).

45. Kawaguchi, S. et al. Oral exposure to low-dose of nonylphenol impairs memory performance in Sprague Dawley rats. *J Toxicol Sci*. **40**, 43–53 (2015).

46. Xu, J. et al. Immune effects of nonylphenol on offspring of rats exposed during pregnancy. *Human & Ecological Risk Assessment*. **16**, 444–452 (2010).

47. Xu, J. et al. Toxic effect of gestational exposure to nonylphenol on F1 male rats. *Birth Defects Res (Part B)*. **89**, 418–428 (2010).

48. Jie, Y. et al. Pollution by Nonylphenol in river, tap water, and aquatic in an acid rain-plagued city in southwest China. *Int J Environ Health Res*. **27**, 179–190 (2017).

49. Tan, B. L., Kassim, N. M. & Mohd, M. A. Assessment of pubertal development in juvenile male rats after sub-acute exposure to bisphenol A and nonylphenol. *Toxicology Letters*. **143**, 261–270 (2003).

Acknowledgements
This work was supported by the foundation of the National Natural Science Foundation of China (81360439); Excellent Youth Science and Technique Talents of Guizhou Province [2017]5612; 2015 Fund for key discipline construction in Zunyi Medical University (No.0996034); Fund of Department of Science and Technology of Guizhou Province, China (LH[2014]7543, LH[2015]7521).

Author Contributions
Xu Jie and Yu Jie designed the study. Yang Xuesong, Xu Jie, Yu Jie, Yang Xuefeng and Yang Mengxue analysed and interpreted the data. Yang Xuesong, Yang Jing and Li Wenmei conducted the laboratory work. Yu Jie, Xu Jie, Wang Pan and Yang Yu participated in the sample collection. Yu Jie wrote the manuscript, and Xu Jie revised the manuscript. All the authors read and approved this paper.

Additional Information
Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.